Valuation: Arctic Bioscience

Market Cap 68.2M 6.98M 6.36M 5.86M 5.33M 10M 646M 10.51M 71.3M 28.34M 353M 26.19M 25.64M 1.11B P/E 2026 *
-2.84x
P/E 2027 * -
Enterprise Value 134M 13.74M 12.51M 11.53M 10.49M 19.67M 1.27B 20.68M 140M 55.77M 695M 51.54M 50.45M 2.18B EV / Sales 2026 *
2.31x
EV / Sales 2027 * -
Free-Float
45.02%
Yield 2026 *
-
Yield 2027 * -
1 day-0.39%
1 week+3.27%
Current month+15.00%
1 month+1.20%
3 months-15.67%
6 months-19.17%
Current year-22.87%
1 week 2.25
Extreme 2.25
2.76
1 month 2.05
Extreme 2.05
2.76
Current year 2.05
Extreme 2.05
3.67
1 year 2.05
Extreme 2.05
3.9
3 years 1.65
Extreme 1.65
16.8
5 years 1.65
Extreme 1.65
21
10 years 1.65
Extreme 1.65
32
Manager TitleAgeSince
Chief Executive Officer 60 01/01/2011
Chief Executive Officer 54 01/03/2022
Director of Finance/CFO 47 01/04/2022
Director TitleAgeSince
Chairman 68 01/12/2015
Director/Board Member 55 01/01/2015
Director/Board Member 46 01/01/2021
Date Insider Type Main position Quantity % Market Cap. Importance
24/04/23 Buy

Director

943,833 3.8641%
24/04/23 Buy

Director

943,833 3.8641%
23/02/23 Buy

Chief Technology Officer

11,500 0.0472%
Change 5-day change 1-year change 3-year change Capi.($)
-0.39%+3.27%-23.33%-72.44% 7.01M
-0.30%-5.62%+28.35%+127.66% 1,204B
+1.25%-4.60%+33.56%+80.57% 643B
+0.94%-2.80%+22.88%+106.94% 501B
-0.60%-2.39%+27.92%+67.00% 378B
+0.69%-9.00%+40.68%+31.42% 327B
+0.41%-4.81%+24.99%+51.91% 285B
+0.81%-3.72%-1.35%+30.72% 270B
-0.15%-6.73%+27.23%+64.15% 237B
-0.06%-0.91%+29.95%+120.58% 207B
Average +0.29%-3.59%+21.09%+60.85% 405B
Weighted average by Cap. +0.39%-4.71%+27.25%+88.32%

Financials

2026 *2027 *
Net sales 58M 5.94M 5.41M 4.98M 4.53M 8.5M 550M 8.94M 60.64M 24.1M 300M 22.28M 21.81M 942M -
Net income -24M -2.46M -2.24M -2.06M -1.88M -3.52M -227M -3.7M -25.09M -9.97M -124M -9.22M -9.02M -390M -
Net Debt 66M 6.76M 6.15M 5.67M 5.16M 9.68M 626M 10.17M 69.01M 27.43M 342M 25.35M 24.81M 1.07B -
Projected Income Statement - Annual - Arctic Bioscience
Logo Arctic Bioscience
Arctic Bioscience AS is a Norway-based biotech company developing and commercializing both pharmaceutical and nutraceutical products based on the properties of herring roe oil. Arctic Bioscience’s purpose is to provide people with autoimmune disorders an effective and healthy therapy based on marine membrane lipids. The Company is developing HRO350 - a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. The Company's product portfolio includes, among others, Romega, which is a producer of an omega-3 dietary supplement made from herring roe in a form of a capsule, as well as herring caviar oil and herring caviar protein offered to Business-to-Business (B2B) customers. Arctic Bioscience AS has three subsidiaries Arctic Nutrition AS, Romega AS and Arctic Biopharma AS.
Employees
19
Date Price Change Volume
20/11/26 NOK 2.530 -0.39% 14,453
19/11/26 NOK 2.540 -5.58% 783
18/11/26 NOK 2.690 0.00% 0
17/11/26 NOK 2.690 -2.54% 1,366
16/11/26 NOK 2.760 +8.66% 264
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
MarketScreener Ratings - Arctic Bioscience

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Arctic Bioscience